VIDEO: Analysis compares phase 3 data of geographic atrophy treatments
Click Here to Manage Email Alerts
In this Healio Video Perspective from the Macula Society meeting, Dilsher Dhoot, MD, discusses data from three phase 3 trials involving pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.
The analysis looked at findings from the phase 3 OAKS and DERBY trials, which included eyes with both nonsubfoveal and subfoveal geographic atrophy (GA) lesions and monthly and every other month dosing of pegcetacoplan, and the GATHER2 trial, which included eyes with nonsubfoveal GA lesions and initial monthly and later monthly and every other month dosing of avacincaptad pegol (ACP).
“Conclusions of this analysis were that pegcetacoplan showed a greater efficacy profile than ACP among patients with nonsubfoveal GA in the analysis,” Dhoot said. “And in the combined meta-analyses, monthly and every other month pegcetacoplan achieved a better efficacy profile at 24 months.”
Collapse
Dhoot D. Pegcetacoplan vs. avacincaptad pegol in geographic atrophy: An anchored matching-adjusted indirect comparison of three phase 3 trials. Presented at: Macula Society meeting; Feb. 7-10, 2024; Palm Springs, California.
Read more about
Click Here to Manage Email Alerts